[go: up one dir, main page]

WO2001047481A1 - Composition de traitement des pellicules - Google Patents

Composition de traitement des pellicules Download PDF

Info

Publication number
WO2001047481A1
WO2001047481A1 PCT/IL2000/000849 IL0000849W WO0147481A1 WO 2001047481 A1 WO2001047481 A1 WO 2001047481A1 IL 0000849 W IL0000849 W IL 0000849W WO 0147481 A1 WO0147481 A1 WO 0147481A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
derivatives
agents
hair
bisabolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2000/000849
Other languages
English (en)
Inventor
Avi Dascalu
Yoram Oron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMASKIN Ltd
Original Assignee
PHARMASKIN Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMASKIN Ltd filed Critical PHARMASKIN Ltd
Priority to AU20216/01A priority Critical patent/AU2021601A/en
Publication of WO2001047481A1 publication Critical patent/WO2001047481A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]

Definitions

  • the present invention relates to a composition for the treatment of seborrheic dermatitis of the scalp (dandruff) Dandruff is a common disease involving a large amount of the population
  • Organ function is totally dependent on an incessant proliferation process accompanied by a metabolic build-up and final apoptosis
  • the proliferation of cells is a continuous mitotic event, regulated by genetically derived forces and by environmental cellular inputs More specifically, the cells respond to a myriad of inputs by selected biochemical transduction pathways Therefore, a final common pathway exists in response to external hormones, cytokines, electrolytes, mechanical stimuli or specific chemicals, etc
  • An imbalance of the cell multiplication process causes diseases Especially the skin may be affected by such imbalances, due to its unique structure and activity which involve total cell turnover about every 50 days in the epidermis and a layer which matures without a direct vascular supply (Greaves and Shuster, eds Springer Verlag 1989 Chapter 1 , pp 14-21)
  • the skin multiplication rate is controlled by its unique feeding on a fibroblast layer of cells in the dermis
  • An imbalance of this process i e an accelerated cell turnover more than the normal rate, generates in skin an incomplete cell maturation process, and results in a thick stratum corneum which causes excessive cellular shedding, known in every day life as squames Squames may be generated by hyperproliferative diseases, such as dandruff which implies an increase of proliferation rate of cells (x 2-3)
  • hyperproliferative diseases such as dandruff which implies an increase of proliferation rate of cells (x 2-3)
  • the exact pathophysiology of rapid multiplication of cells is unknown
  • Zinc pyrithione empirical formula C ⁇ 0 H ⁇ 0 N 2 O 2 S 2 Zn, name b ⁇ s(1-hydroxy-2(1 H)-py ⁇ d ⁇ neth ⁇ onato) zinc or zinc, b ⁇ s(2-py ⁇ dylth ⁇ o)-N-ox ⁇ de) and its derivatives are known as antiproliferative/cytotoxic agents, as described in USP Dl Volume I, Drug Information for the Health Care Professional, DE400, (Revised 08/13/98), and piroctone olamine, empirical formula C ⁇ 4 H 23 NO 2 • C 2 H 7 NO name 1-hydroxy-4-methyl-6-(2,4,4-t ⁇ methylpentyl)-2-(1 H)pyr ⁇ d ⁇ none, 2-am ⁇ noethanol salt, or its derivatives, such as piroctone monoethanolamine, are cytotoxic, as well and were formerly used as preservatives and biocides
  • composition which can directly inhibit proliferation of the dermal layer, which is the real skin proliferation controller, to a greater extent than existing treatments
  • Such composition should cause the recovery of cells from their pathological hyperproliferative state and restore a normal multiplication rate Since seborrheic dermatitis is also an inflammatory process, an additional cytotoxic agent, which possesses also anti-inflammatory attributes should be part of the composition
  • the present invention thus consists in a composition for the treatment of seborrheic dermatitis of scalp (dandruff) comprising a mixture of bisabolol, one of its derivatives or compounds comprising same with zinc pyrithione and piroctone olamine and/or their derivatives.
  • the bisabolol may be part of a Chamomile extract.
  • the composition according to the present invention comprises :
  • Bisabolol (either pure or racemic) , from 0.001-25 % (all percentages are indicated herein in w/w), preferably between 0.01-10 % and advantageously between 0.05-1.0 % by weight; or a chamomile extract, from 0.001-75 %, preferably between 0.01-25 % and advantageously between 0.1-5 % by weight;
  • Zinc pyrithione in a concentration from 0.001-20.0 %, preferably between 0.1-5
  • Piroctone olamine in a concentration from 0.001-20.0 %, preferably between 0.05-5 % and advantageously between 0.2-2% by weight.
  • composition according to the present invention may be topically applied as such or internally ingested within a suitable carrier, solvent, emulgent, extract, a solution e.g. water, alcohol, an oil, a suspension; microemulsions, microcapsules, vesicles, etc.
  • the active agents may be formulated into various compositions, e.g. a lotion, a conditioner, a hair tonic, a shampoo, a lotion with conditioner, a gel, a styling gel, a mousse, a styling wax, a mask, an aerosol, a moisturizer, a powder, a perfume, a brilliantine, a pomade, a dye, a cream, an ointment, etc.
  • composition according to the present invention might be formulated, e. g. as an internally ingested tablet, capsule, drops or suspension.
  • composition can be used alone or in conjunction with a pharmaceutical effective compound selected among: 1 Keratolytic agents such as salicylic acid, sulphur, resorcinol, selenium, alpha hydroxy-carboxy c acids, etc ,
  • Antifungals e g ciclopyroxolamine, azoles (such as ketoconazole, bifonazole) metronidazole, undecylenic acid and derivatives of the said compounds, etc
  • Antimicrobials e g aluminium chloride, chlorothymol, hexamine, zinc salycilate, zinc sulphide, t ⁇ clorocarban, tnclosan, etc ,
  • Germicides such as phenols, hydroxyquinolones, undecenoic acids, etc .
  • Anti irntancy agents such as t ⁇ terpenes, polycichc polyenes or saponms, etc .
  • Anti-inflammatory agents e g cyclo-oxygenase inhibitors, panthenol, comilower extract, guaiazulene, etc .
  • Sterols e g medicated low (hydrocortisone), intermediate (mometasone) to high (betamethasone, dexamethasone), potency steroids, of plant origin e g phytosterols such as glycyrrhizic acid and derivatives, etc ,
  • Hair nourishment agents such as vitamins, e g tocopherol (Vitamin E) and its derivatives, Vitamin B6, vitamin C, biotin, pantothenic acid, Vitamin D and its derivatives, ammo acids e g arginine, citrulline, ornithine, se ⁇ ne and methionine, organic acids, e g lactate or malate, minerals and metals, e g zinc and its derivatives, magnesium, aluminum, death sea minerals, eugenol polyamines and antioxidants, etc ,
  • Lipid derivatives e g mineral oil, vegetable oil, animal and synthetic oil, fatty alcohol, saturated and unsaturated fatty acids, waxes, squalene, etc ,
  • Herbal extracts which restore the skin natural protective factor ability such as aloe vera, rosemary, tea tree oil or thyme, etc .
  • Vasodilating compounds or nitric oxide donors e g of natural source (arginine) or medicated (nitroprusside, sodium nitrite), etc , and
  • Hair stimulating and /or hair invigorating agents e g saw palmetto diazoxide, glycirrhizic acid or 5 alpha reductase inhibitors, etc
  • composition according to the present invention may be prepared by conventional methods, as becomes apparent from the Experiments given hereinafter
  • the composition according to the present invention is suitably applied in portions of about 1 - 10 ml/daily from 1-7 times weekly, advantageously 5 ml/daily each other day.
  • the present invention consists also in the use of a composition according to the present invention for the treatment of humans and animals against seborrheic dermatitis.
  • the present invention consists also in a method for the treatment of humans and animals against seborrheic dermatitis with a composition according to the present invention.
  • Fibroblast cells the feeding layer of the skin, were exposed to the addition of bisabolol, piroctone olamine and zinc pyrithione.
  • Bisabolol alone was not antiproliferative. Whenever bisabolol was added to cells previously treated with piroctone olamine and zinc pyrithione, the unexpected conversion of bisabolol into an antiproliferative agent was observed.
  • the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) colorimethc reaction is based on the uptake of tetrazolium salt exclusively by live cells and its reduction to a soluble violet (formazan) compound.
  • the absorbance of formazan is proportional to the amount of active mitochondrial enzyme succinate-dehydrogenase of the cells and cell viability.
  • Fibroblast 3T3 cells were seeded at 30000 cells/well in 96-well microtiter wells (Corning) and grown until confluence.
  • the absorbance spectrum of MTT was determined by a diode array spectrophotometer (Hewlett Packard, 8452A).
  • MTT exhibited peak absorbance at 560 nm and minimal readings beyond 620 nm, as previously shown.
  • a microplate reader (Thermomax, Molecular Devices) was used to read absorbance at 550 nm with background subtraction at a reference absorbance of 650 nm at 25 EC (Methodology in Dascalu A, Peer A, Academic Radiology, 1 :140-145, 1994).
  • Figure 1a demonstrates that addition of 0 2 ⁇ g/ml - 0 4 g ⁇ g/ml piroctone olamine doesn't cause any effects on cellular viability (a threefold concentration of 1 2 ⁇ g/ml caused a 10% decrease of cell viability, data not shown) Zinc pyrithione did not cause any cytotoxic effect at 0 2 ⁇ g/ml, but at 0 4 ⁇ g/ml a 10 % decrease of viability was observed (Fig 1 b) Therefore, we employed a concentration of 0 2 ⁇ g/ml zinc pyrithione and 0 2 ⁇ g/ml of piroctone olamine, which did not affect fibroblast viability (Fig 1 c)
  • Figure 3 demonstrates that at a concentration of 0.05% Bisabolol, no effects on cell viability can be seen. However, above this concentration, at 0.1 , 0.4 and 1.0 %, an increased damage to cellular viability is observed (Figure 3, p ⁇ 0.05).
  • Exemplary formula for topical formulation of a composition according to the present invention in a shampoo based formula is illustrated in FIG. 1 .
  • Exemplary formula for topical formulation of a composition according to the present invention in a creamy based formula is illustrated in FIG. 1 .
  • composition according to the topical formulation according to the present invention in a shampoo formula with a hair invigorating compound a hair invigorating compound

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition de traitement de dermatites séborrhéiques du cuir chevelu (pellicules), laquelle comprend un mélange de bisabolol, un dérivé ou composé de celui-ci comprenant le bisabolol ainsi que du pyrithione de zinc et de la piroctone olamine, et/ou des dérivés de ceux-ci. De manière avantageuse, cette composition comprend 0,001 à 20 % de pyrithione de zinc et 0,02 à 20 % de piroctone olamine. De préférence, le bisabolol est un extrait de camomille. Cette composition peut comporter également un composé efficace sur le plan pharmacologique, choisi dans le groupe constitué par des agents kératolytiques, anti-prolifératifs, antifongiques, antimicrobiens, germicides, anti-irritants, anti-inflammatoires, des stérols, des agents de nutrition des cheveux, des dérivés lipidiques, des agents à effet refroidissant, des extraits d'herbes, des composés vasodilatateurs, des donneurs de monoxyde d'azote et des agents stimulant la pousse des cheveux et/ou fortifiant les cheveux. L'invention concerne également le traitement de l'homme et de l'animal contre les dermatites séborrhéiques, ainsi qu'un procédé de traitement associé.
PCT/IL2000/000849 1999-12-28 2000-12-20 Composition de traitement des pellicules Ceased WO2001047481A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20216/01A AU2021601A (en) 1999-12-28 2000-12-20 Composition for the treatment of dandruff

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL133760A IL133760A (en) 1999-12-28 1999-12-28 Composition for the treatment of dandruff
IL133760 1999-12-28

Publications (1)

Publication Number Publication Date
WO2001047481A1 true WO2001047481A1 (fr) 2001-07-05

Family

ID=11073647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000849 Ceased WO2001047481A1 (fr) 1999-12-28 2000-12-20 Composition de traitement des pellicules

Country Status (3)

Country Link
AU (1) AU2021601A (fr)
IL (1) IL133760A (fr)
WO (1) WO2001047481A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059297A3 (fr) * 2002-01-21 2003-12-18 Slovakofarma As Compositions dermatologiques topiques et procede pour leur preparation
WO2004006876A1 (fr) * 2002-07-15 2004-01-22 Unilever Plc Composition pour le traitement des cheveux et/ou du cuir chevelu
FR2899794A1 (fr) * 2006-04-14 2007-10-19 Jean Noel Thorel Composition cosmetique capillaire
WO2008047394A1 (fr) * 2006-10-16 2008-04-24 Opocrin S.P.A. Compositions pour l'hygiène des paupières et l'hygiène périoculaire à tolérabilité oculaire et cutanée améliorée
WO2008105632A1 (fr) 2007-02-27 2008-09-04 Biospectrum Inc. Compositions pour améliorer des conditions cutanées renfermant de l'alpha-bisabolol en tant que principe actif
WO2014139358A1 (fr) * 2013-03-14 2014-09-18 The Procter & Gamble Company Composition de savon en pain contenant de la pyrithione de zinc et un complexe métal-oxyde de pyridine
FR3005575A1 (fr) * 2013-05-20 2014-11-21 Oreal Composition cosmetique comprenant un agent antipelliculaire, un bisabolol et un compose de type madecassoside, et procede de traitement cosmetique
KR20160060255A (ko) * 2014-11-19 2016-05-30 주식회사 씨앤피코스메틱스 두피 개선용 화장료 조성물 및 이를 이용한 두피 트리트먼트 방법
WO2017191629A1 (fr) 2016-05-02 2017-11-09 Y&B Mother's Choice Ltd. Compositions de saponines et d'extraits de plantes
US11246817B2 (en) 2016-08-19 2022-02-15 Conopco, Inc. Antimicrobial composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158481A2 (fr) * 1984-03-28 1985-10-16 THE PROCTER & GAMBLE COMPANY Compositions pour soins capillaires
JPS63179813A (ja) * 1987-01-21 1988-07-23 Eikoudou:Kk 毛髪化粧料
DE4133085A1 (de) * 1991-07-15 1993-04-01 Franco Mengoli Heilkraeuter enthaltende kosmetische zusammensetzung und verfahren zu deren herstellung
FR2741265A1 (fr) * 1995-11-17 1997-05-23 Fabre Pierre Dermo Cosmetique Association extrait de myrte et antifongiques
WO1998050005A1 (fr) * 1997-05-09 1998-11-12 Medlogic Global Corporation Compositions pour applications cosmetiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158481A2 (fr) * 1984-03-28 1985-10-16 THE PROCTER & GAMBLE COMPANY Compositions pour soins capillaires
JPS63179813A (ja) * 1987-01-21 1988-07-23 Eikoudou:Kk 毛髪化粧料
DE4133085A1 (de) * 1991-07-15 1993-04-01 Franco Mengoli Heilkraeuter enthaltende kosmetische zusammensetzung und verfahren zu deren herstellung
FR2741265A1 (fr) * 1995-11-17 1997-05-23 Fabre Pierre Dermo Cosmetique Association extrait de myrte et antifongiques
WO1998050005A1 (fr) * 1997-05-09 1998-11-12 Medlogic Global Corporation Compositions pour applications cosmetiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UEDA, GOROSAKU: "Cosmetic hair preparations containing piroctone olamine and water-soluble sulfur and/or UV absorbers", XP002164477, retrieved from STN Database accession no. 110:160216 CA *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059297A3 (fr) * 2002-01-21 2003-12-18 Slovakofarma As Compositions dermatologiques topiques et procede pour leur preparation
WO2004006876A1 (fr) * 2002-07-15 2004-01-22 Unilever Plc Composition pour le traitement des cheveux et/ou du cuir chevelu
FR2899794A1 (fr) * 2006-04-14 2007-10-19 Jean Noel Thorel Composition cosmetique capillaire
WO2008047394A1 (fr) * 2006-10-16 2008-04-24 Opocrin S.P.A. Compositions pour l'hygiène des paupières et l'hygiène périoculaire à tolérabilité oculaire et cutanée améliorée
WO2008105632A1 (fr) 2007-02-27 2008-09-04 Biospectrum Inc. Compositions pour améliorer des conditions cutanées renfermant de l'alpha-bisabolol en tant que principe actif
EP2124872A4 (fr) * 2007-02-27 2011-12-21 Biospectrum Inc Compositions pour améliorer des conditions cutanées renfermant de l'alpha-bisabolol en tant que principe actif
WO2014139358A1 (fr) * 2013-03-14 2014-09-18 The Procter & Gamble Company Composition de savon en pain contenant de la pyrithione de zinc et un complexe métal-oxyde de pyridine
US9333157B2 (en) 2013-03-14 2016-05-10 The Procter & Gamble Company Bar soap compositions containing zinc pyrithione and a metal-pyridine oxide complex
US9655831B2 (en) 2013-03-14 2017-05-23 The Procter & Gamble Company Bar soap compositions containing zinc pyrithione and a metal-pyridine oxide complex
FR3005575A1 (fr) * 2013-05-20 2014-11-21 Oreal Composition cosmetique comprenant un agent antipelliculaire, un bisabolol et un compose de type madecassoside, et procede de traitement cosmetique
KR20160060255A (ko) * 2014-11-19 2016-05-30 주식회사 씨앤피코스메틱스 두피 개선용 화장료 조성물 및 이를 이용한 두피 트리트먼트 방법
KR101637466B1 (ko) * 2014-11-19 2016-07-11 주식회사 씨앤피코스메틱스 두피 개선용 화장료 조성물 및 이를 이용한 두피 트리트먼트 방법
WO2017191629A1 (fr) 2016-05-02 2017-11-09 Y&B Mother's Choice Ltd. Compositions de saponines et d'extraits de plantes
KR20190006985A (ko) 2016-05-02 2019-01-21 와이앤드비 마더스 초이스 엘티디. 사포닌 및 식물 추출물의 조성물
US11246817B2 (en) 2016-08-19 2022-02-15 Conopco, Inc. Antimicrobial composition

Also Published As

Publication number Publication date
AU2021601A (en) 2001-07-09
IL133760A0 (en) 2001-04-30
IL133760A (en) 2007-10-31

Similar Documents

Publication Publication Date Title
KR100638536B1 (ko) 모발 및/또는 두피용 조성물
EP1035828B1 (fr) Compositions topiques destinees a minimiser l'aspect gras/luisant de la peau
EP1948236B1 (fr) Procedes et compositions pour le traitement de la peau
FI115606B (fi) NO-syntaasin estäjät
CZ342298A3 (cs) Způsob upravování sravu pleti pomocí sloučeniny vitaminu B3
CN102256666B (zh) 治疗皮肤病症的组合物和方法
JP2002506801A (ja) 哺乳類の皮膚のセルライトを軽減する方法
WO2019166089A1 (fr) Produit dermatologique
US20080260864A1 (en) Topical Compositions for the Treatment of Depilation-Induced Irritation or Prevention Thereof
US7166300B1 (en) Agent for inducing hair growth containing extracts of saw palmetto and swertia
BRPI1004113A2 (pt) composiÇço de peràxido de benzoÍla para tratamento de pele
JP2002506821A (ja) 皮膚刺激の治療方法
US12447189B2 (en) Topical skin care composition
JP2005507882A (ja) 皮膚不調の治療方法
WO2001047481A1 (fr) Composition de traitement des pellicules
CN101229105A (zh) 几种二硫杂环戊二烯硫酮类和异硫氰酸酯类化合物在治疗灰发症中的用途
WO2000051554A2 (fr) Regulation de l'aspect de la peau et composition contenant un compose d'analogue de vitamine d3 fluore
US20050238613A1 (en) Composition, in particular cosmetic, comprising DHEA and/or a precursor or derivative thereof, combined with at least a no-synthase inhibitor
EP0998907B1 (fr) Tonique pour cheveux comprenant de l'adénosine
JPS61183206A (ja) 化粧料
JPS59172411A (ja) 脂肪酸含有養毛組成物
IL308075A (en) Topical formulations comprising benzoyl peroxide and azelaic acid, and use thereof
JP2004534069A (ja) Ｎｏ−シンターゼインヒビターとその用途
JP2005501818A (ja) Ｎｏ−シンターゼインヒビターとしての２−ヘキサデカン酸アスコルビル
CZ20001358A3 (cs) Prostředek k místnímu použití pro snížení nadměrné činnosti mazových žláz

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP